Business Context and Reporting Period
Company: Acacia Research Corporation
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2001
Business Overview: Acacia develops and operates life science and enabling technology companies. Key subsidiaries include CombiMatrix (biochip technology), Soundview Technologies (telecommunications/V-chip patents), and Greenwich Information Technologies (video/audio-on-demand patents). The company recently increased its ownership of Greenwich Information Technologies to 100% in November 2001.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Sep 30, 2001 | 9 Months Ended Sep 30, 2001 | 9 Months Ended Sep 30, 2000 |
|---|---|---|---|
| Total Revenues | $10,831 | $23,545 | $57 |
| Operating Expenses | $18,527 | $56,691 | $19,281 |
| Operating Loss | $(7,696) | $(33,146) | $(19,224) |
| Net Loss | $(2,827) | $(17,078) | $(20,942) |
| Net Loss Per Share (Basic/Diluted) | $(0.14) | $(0.89) | $(1.31) |
| Cash and Cash Equivalents | $40,234 | $40,234 | $35,953 (Dec 31, 2000) |
| Short-term Investments | $49,567 | $49,567 | $40,600 (Dec 31, 2000) |
| Total Liabilities | $47,949 | $47,949 | $20,848 (Dec 31, 2000) |
| Working Capital | $51,634 | $51,634 | $59,865 (Dec 31, 2000) |
Note: Working capital calculated as Total Current Assets ($93,845) minus Total Current Liabilities ($42,211).
Material Changes vs. Prior Period
- Revenue Surge: Total revenues for the nine months ended September 30, 2001, increased to $23.5 million from $57,000 in the prior year. This is primarily driven by $23.2 million in license fee income from Soundview Technologies' V-chip patent settlements and licensing agreements with major manufacturers (e.g., Samsung, Hitachi, Matsushita).
- Expense Growth: Operating expenses rose significantly to $56.7 million for the nine months ended September 30, 2001, compared to $19.3 million in 2000. This increase is attributed to:
- Expansion of CombiMatrix's R&D and personnel.
- Non-cash stock compensation charges of $20.8 million (nine months 2001) versus $2.8 million (nine months 2000), resulting from a revaluation of CombiMatrix stock options.
- Increased legal fees related to patent settlements.
- Net Loss Improvement: Despite higher expenses, the net loss for the nine months ended September 30, 2001, decreased to $17.1 million from $20.9 million in the prior year, aided by minority interest allocations and interest income.
- Liquidity: Cash and short-term investments totaled approximately $89.8 million as of September 30, 2001, providing a strong liquidity position.
Guidance, Outlook, and Risks
- Outlook: Management anticipates that existing working capital reserves will fund operations for at least the next twelve months. Future capital needs for new businesses may require additional equity or debt financing, which could be dilutive.
- Future Stock Compensation: Approximately $20.8 million in deferred non-cash stock compensation charges remain to be amortized over the next thirteen quarters (through 2004), which will continue to impact reported earnings.
- Legal Proceedings:
- Soundview Technologies: Ongoing litigation against Sony and others regarding V-chip patents. Several major manufacturers have already settled or licensed the technology.
- CombiMatrix: Facing a lawsuit from Nanogen, Inc., alleging trade secret misappropriation and patent ownership disputes. CombiMatrix has filed a counterclaim and intends to defend vigorously.
- Accounting Changes: The company will adopt SFAS No. 142 (Goodwill) effective January 1, 2002, which will stop goodwill amortization and require periodic impairment testing. The impact is currently unknown.
- Subsequent Events: A 10% stock dividend was declared on October 22, 2001, payable December 5, 2001. CombiMatrix formed a joint venture with Marubeni Japan in October 2001.
Investor Verification Checklist
- Revenue Sustainability: Verify the terms of the Soundview Technologies license agreements to determine if the $23.2 million in license fees represents a one-time settlement or recurring royalty income.
- Stock Compensation Impact: Review the amortization schedule for the remaining $20.8 million in deferred stock compensation to understand future non-cash expense burdens.
- Legal Risks: Monitor the status of the Nanogen lawsuit against CombiMatrix, as an adverse outcome could threaten core intellectual property.
- Minority Interest Fluctuations: Analyze the significant minority interest allocations ($14.4 million for nine months 2001) to understand the true economic loss attributable to Acacia shareholders versus minority partners in subsidiaries.
- Cash Burn Rate: Assess the net cash used in operating activities ($8.4 million for nine months) against the $89.8 million cash balance to confirm the runway for operations.